Literature DB >> 536450

Application of a simple high-performance liquid chromatographic method for the determination of melphalan in the presence of its hydrolysis products.

K P Flora, S L Smith, J C Cradock.   

Abstract

A procedure for the separation and quantitation of melphalan (L-PAM) and its hydrolysis products by high-performance liquid chromatography is described. The hydrolysis of L-PAM at 25 +/- 0.1 degrees and 41 +/- 0.1 degrees was studied between pH 3.0 and 9.0. The pattern of hydrolysis suggested that L-PAM decomposes via two consecutive pseudo first-order reactions. Pseudo first-order rate constants (k1) were determined for the disappearance of L-PAM at various pH values in buffered solutions and in a formulated product. At both temperatures L-PAM solutions were found to be most stable at low pH. Chloride ion was found to reduce the rate of hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 536450     DOI: 10.1016/s0021-9673(00)92602-5

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.

Authors:  W P Peters; A Stuart; M Klotman; C Gilbert; R B Jones; E J Shpall; J Gockerman; R C Bast; J O Moore
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits.

Authors:  I A Taha; R A Ahmad; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Pharmacokinetics of melphalan in children following high-dose intravenous injection.

Authors:  I A Taha; R A Ahmad; D W Rogers; J Pritchard; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 6.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.

Authors:  I A Taha; R A Ahmad; H Gray; C I Roberts; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.